Biocodex invests in live biotherapeutics production at Beauvais plant

Biocodex announced a major investment to produce live biotherapeutic products at its Beauvais plant, targeting first clinical batches by 2028. This marks a strategic expansion into an emerging market, leveraging its microbiology expertise. The move signals growing industrial capacity in France for advanced therapies, though financial details and capacity specifics remain undisclosed.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works